2013 | 2012 | ||||||||||||||||||||||||
(Dollars in Millions Except Per Share Data) | First Quarter (1) | Second Quarter (2) | Third Quarter (3) | Fourth Quarter (4) | First Quarter (5) | Second Quarter (6) | Third Quarter (7) | Fourth Quarter (8) | |||||||||||||||||
Segment sales to customers | |||||||||||||||||||||||||
Consumer | $ | 3,675 | 3,658 | 3,611 | 3,753 | 3,595 | 3,619 | 3,581 | 3,652 | ||||||||||||||||
Pharmaceutical | 6,768 | 7,025 | 7,036 | 7,296 | 6,133 | 6,291 | 6,402 | 6,525 | |||||||||||||||||
Med Devices & Diagnostics | 7,062 | 7,194 | 6,928 | 7,306 | 6,411 | 6,565 | 7,069 | 7,381 | |||||||||||||||||
Total sales | 17,505 | 17,877 | 17,575 | 18,355 | 16,139 | 16,475 | 17,052 | 17,558 | |||||||||||||||||
Gross profit | 11,951 | 12,388 | 12,231 | 12,400 | 11,224 | 11,332 | 11,455 | 11,555 | |||||||||||||||||
Earnings before provision for taxes on income | 4,261 | 4,793 | 3,667 | 2,750 | 5,045 | 2,035 | 3,595 | 3,100 | |||||||||||||||||
Net earnings attributable to Johnson & Johnson | 3,497 | 3,833 | 2,982 | 3,519 | 3,910 | 1,408 | 2,968 | 2,567 | |||||||||||||||||
Basic net earnings per share attributable to Johnson & Johnson | $ | 1.25 | 1.36 | 1.06 | 1.25 | 1.43 | 0.51 | 1.08 | 0.93 | ||||||||||||||||
Diluted net earnings per share attributable to Johnson & Johnson | $ | 1.22 | 1.33 | 1.04 | 1.23 | 1.41 | 0.50 | 1.05 | 0.91 |
(1) | The first quarter of 2013 includes after-tax charges of $183 million from Synthes integration/transaction costs, $391 million from net litigation expense and $42 million from impairment of in-process research and development, and $30 million associated with the DePuy ASR™ Hip program. |
(2) | The second quarter of 2013 includes after-tax charges of $308 million from net litigation expense, $87 million from Synthes integration/transaction costs and $61 million associated with the DePuy ASR™ Hip program. |
(3) | The third quarter of 2013 includes after-tax charges of $720 million from net litigation expense, $103 million from Synthes integration/transaction costs, $126 million from impairment of in-process research and development and $31 million associated with the DePuy ASR™ Hip program. |
(4) | The fourth quarter of 2013 includes after-tax charges of $227 million from net litigation expense, $110 million from Synthes integration/transaction costs, $294 million from impairment of in-process research and development, $118 million associated with the DePuy ASR™ Hip program and a $707 million tax benefit associated with Scios Inc. |
(5) | The first quarter of 2012 includes an after-tax gain of $106 million from currency and costs associated with the acquisition of Synthes, Inc. |
(6) | The second quarter of 2012 includes after-tax charges of $717 million for asset write-downs, $611 million from net litigation expense, $564 million associated with the acquisition of Synthes, Inc. and $344 million from impairment of in-process research and development. |
(7) | The third quarter of 2012 includes after-tax charges of $135 million associated with the acquisition of Synthes, Inc., $340 million from impairment of in-process research and development, $70 million associated with net litigation expense, and $24 million associated with the DePuy ASR™ Hip program. |
(8) | The fourth quarter of 2012 includes after-tax charges of $371 million from net litigation expense, $306 million associated with the acquisition of Synthes, Inc., $73 million associated with the DePuy ASR™ Hip program and $59 million from impairment of in-process research and development. |